Latest News

Morgan Stanley downgrades Bristol-Myers Squibb on drug pipeline concern


The New York Stock Exchange welcomes Bristol Myers Squibb on Nov. 20th, 2020.


Uncertainty around future drug developments could hold back the stock price of Bristol-Myers Squibb, according to Morgan Stanley.

Analyst David Risinger downgraded the stock to equal weight from overweight on Friday, saying that the long-term picture for the company’s earnings power was getting less positive.

Burger King parent’s earnings beat estimates as systemwide sales top 2019 levels

Previous article

Robinhood deepens ties with JPMorgan by using bank for money transfers ahead of expected IPO

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News